Bulk Pharmaceutical API Sources for TIBSOVO

Bulk Pharmaceutical API Sources for TIBSOVO

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-18767
AbaChemScene		CS-5122
abcr GmbH		AB402598
ChemShuttle		140519

Bulk Active Pharmaceutical Ingredient (API) Sources for TIBSOVO

Last updated: February 19, 2026

This report identifies and analyzes key suppliers of the bulk active pharmaceutical ingredient (API) for TIBSOVO (ivosidenib). It focuses on manufacturing capabilities, regulatory compliance, and geographic distribution of potential API sources relevant to pharmaceutical companies seeking to secure supply chains for this oncology drug.

What is TIBSOVO (ivosidenib) and its API?

TIBSOVO, developed by Agios Pharmaceuticals, is an isocitrate dehydrogenase 1 (IDH1) inhibitor. It is prescribed for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and for newly diagnosed AML in combination with standard cytarabine and idarubicin, in adults 75 years or older or those unable to receive intensive induction chemotherapy. The API for TIBSOVO is ivosidenib. Ivosidenib's chemical name is N-(5-((3,3-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-2-((4-(methylsulfonyl)phenyl)amino)phenyl)-3-methyl-1H-indazole-5-carboxamide. The drug targets mutated forms of IDH1, an enzyme involved in cellular metabolism and differentiation. Inhibiting these mutated enzymes helps to restore normal cellular function, leading to the differentiation of myeloid blasts into mature cells.

What are the primary challenges in sourcing ivosidenib API?

The sourcing of ivosidenib API is subject to several critical challenges inherent in the pharmaceutical API market, particularly for targeted oncology therapies:

• Manufacturing Complexity: The synthesis of ivosidenib involves multi-step chemical processes requiring specialized equipment, stringent quality control, and expertise in handling complex organic molecules. This complexity limits the number of potential manufacturers with the necessary technical capabilities.
• Regulatory Hurdles: API manufacturing for pharmaceuticals requires strict adherence to Good Manufacturing Practices (GMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. Obtaining and maintaining GMP certification is a significant barrier to entry and requires substantial investment in infrastructure and quality systems. Manufacturers must also pass rigorous inspections and provide detailed documentation on their manufacturing processes, analytical methods, and impurity profiles.
• Intellectual Property (IP) Landscape: While the primary patents protecting TIBSOVO's composition of matter and its use may be approaching expiration or have already expired in certain jurisdictions, patents covering specific polymorphs, synthesis routes, or formulations can still influence API sourcing. Manufacturers must navigate this IP landscape to avoid infringement.
• Supply Chain Security and Redundancy: Ensuring a consistent and secure supply of critical APIs like ivosidenib is paramount. Pharmaceutical companies seek manufacturers that can demonstrate robust supply chain management, risk mitigation strategies, and the capacity to scale production. Dependence on a single source or region presents a significant risk.
• Cost and Economies of Scale: The cost of producing complex APIs can be high, influenced by raw material prices, manufacturing yields, and regulatory compliance costs. Achieving economies of scale is crucial for competitive pricing, which can favor larger, more established API manufacturers.
• Geopolitical Factors: Global supply chains are susceptible to geopolitical instability, trade disputes, and changes in regulatory policies. Sourcing from diverse geographic regions can help mitigate these risks, but also introduces complexities in logistics and oversight.

Who are the potential bulk API manufacturers for ivosidenib?

The manufacturing of ivosidenib API is primarily concentrated among Contract Development and Manufacturing Organizations (CDMOs) and specialized API producers. Due to the proprietary nature of pharmaceutical manufacturing and supply agreements, a comprehensive public list of all current suppliers is not readily available. However, based on industry analysis, regulatory filings, and common practices for branded oncology drugs, several types of entities are likely involved or could be qualified.

Key Categories of Potential Manufacturers:

• Established CDMOs with Oncology Expertise: These organizations possess the technical infrastructure, regulatory experience, and capacity to handle complex multi-step syntheses and meet stringent GMP requirements.
• Asian-Based API Manufacturers (India and China): These regions are dominant in global API production due to cost advantages and established manufacturing capabilities. Many possess significant GMP compliance and have historically supplied APIs for both generic and branded pharmaceuticals.
• European and North American Manufacturers: While often operating at a higher cost base, these manufacturers offer proximity, potentially faster regulatory pathways in their respective regions, and strong GMP track records, which can be attractive for certain supply chain strategies.

Specific Companies and Considerations:

While specific company names directly supplying ivosidenib API are typically confidential contractual arrangements, the following are representative of the types of organizations that possess the capabilities and often engage in such manufacturing:

1. Lonza: Lonza is a global CDMO with extensive experience in complex small molecule synthesis and a strong regulatory track record. They have manufacturing sites in Europe and North America and are known for their capabilities in handling high-potency APIs, which can be relevant for oncology drugs. Lonza's services span from early-stage process development to large-scale commercial manufacturing. Their regulatory expertise with FDA and EMA submissions is a significant advantage.

2. Catalent: Catalent is another major global CDMO offering comprehensive API development and manufacturing services. They have a significant presence in North America and Europe and are experienced in handling a wide range of chemical syntheses. Catalent's network of facilities allows for flexible capacity and diverse technological capabilities. Their focus on quality and regulatory compliance aligns with the demands for oncology APIs.

3. WuXi AppTec: WuXi AppTec is a leading China-based CDMO providing a broad range of R&D and manufacturing services. They have a substantial footprint in API manufacturing, including complex molecules, and have invested heavily in upgrading their facilities to meet international GMP standards. Their competitive pricing and large-scale capacity make them a significant player in the global API market. They are frequently audited by major pharmaceutical companies and regulatory bodies.

4. Divi's Laboratories: Divi's Laboratories, an India-based API manufacturer, is recognized for its large-scale production capabilities and cost-effectiveness. While their primary focus has often been on generic APIs, they also engage in custom synthesis and the manufacturing of intermediates for novel drugs. Their extensive experience with regulatory filings and large-scale plant operations positions them as a potential supplier for APIs requiring significant volume.

5. Granules India: Granules India is another prominent Indian pharmaceutical company with a strong API manufacturing division. They specialize in a range of therapeutic areas and have a robust GMP compliance framework. Their focus on backward integration and efficient manufacturing processes allows for competitive cost structures, making them a viable option for high-volume API sourcing.

6. Siegfried AG: Siegfried is a Swiss-based CDMO with a global presence, including facilities in Europe and North America. They offer custom development and manufacturing of APIs and finished dosage forms, with a particular emphasis on complex chemistries and regulated markets. Their long history and established quality systems are a key asset.

Table 1: Representative API Manufacturers with Relevant Capabilities

Company Name	Primary Geographic Focus	Key Strengths	Relevant Expertise
Lonza	Global (Europe, NA)	Complex synthesis, High-potency APIs, Regulatory compliance	Multi-step organic synthesis, Oncology APIs
Catalent	Global (NA, Europe)	Broad API development & manufacturing, Scalability, Quality	Diverse chemical synthesis, API process optimization
WuXi AppTec	Global (Asia, NA, Europe)	Large-scale capacity, Cost-effectiveness, Broad service offering	Complex molecule synthesis, GMP manufacturing
Divi's Laboratories	Global (India)	High-volume production, Cost efficiency, Process optimization	Bulk API manufacturing, Intermediate synthesis
Granules India	Global (India)	Cost-competitiveness, GMP compliance, Backward integration	Large-scale API production, Generic API expertise
Siegfried AG	Global (Europe, NA)	Custom synthesis, Regulated markets, Complex chemistry	API development & manufacturing, High-quality standards

Note: This table lists representative companies based on their known capabilities in API manufacturing and their typical market engagement. Direct supply agreements for ivosidenib are proprietary.

What are the regulatory considerations for API sourcing?

Sourcing bulk API for a branded pharmaceutical like TIBSOVO necessitates strict adherence to global regulatory standards to ensure drug safety, efficacy, and quality. The primary regulatory framework governing API manufacturing is Good Manufacturing Practices (GMP).

Key Regulatory Requirements:

• GMP Compliance: Manufacturers must operate under GMP guidelines as defined by regulatory agencies such as the FDA (21 CFR Parts 210 and 211), EMA (EudraLex Volume 4), and others. This includes robust quality management systems, controlled manufacturing environments, validated processes, and detailed batch records.
• Drug Master File (DMF) / Active Substance Master File (ASMF): API manufacturers typically submit a DMF (in the US) or an ASMF (in Europe) to regulatory authorities. This confidential document contains detailed information about the manufacturing process, quality control, and stability of the API. The drug product manufacturer (e.g., Agios or its partners) references this DMF/ASMF in their drug application.
• Site Inspections and Audits: Regulatory agencies conduct periodic inspections of API manufacturing facilities to ensure ongoing GMP compliance. Pharmaceutical companies also conduct their own audits of potential and existing API suppliers to verify quality, reliability, and capacity.
• Impurity Profiling and Control: Rigorous analytical methods are required to identify, quantify, and control impurities in the API. Regulatory guidelines (e.g., ICH Q3A) set thresholds for reporting, identification, and qualification of impurities. The control of genotoxic impurities is particularly critical.
• Change Control: Any significant changes to the API manufacturing process, raw materials, or analytical methods must be managed through a formal change control system and may require notification or approval from regulatory authorities and the drug product manufacturer.
• Supply Chain Traceability: Pharmaceutical companies must ensure traceability of their API supply chain, from raw materials to the finished API. This involves maintaining detailed records and ensuring that suppliers have their own robust traceability systems.
• Stability Studies: Comprehensive stability studies are required to determine the shelf life of the API under various storage conditions, adhering to ICH Q1 guidelines.

API Manufacturers' Role in Regulatory Submissions:

API manufacturers play a crucial role in supporting the regulatory submissions of drug product manufacturers. They provide:

• Detailed manufacturing process descriptions.
• Analytical methods and validation data.
• Impurity profiles and control strategies.
• Stability data.
• Information on raw material sourcing and control.

The quality and completeness of the information provided in the DMF/ASMF are critical for the successful approval of the drug product by regulatory agencies.

What are the geographic concentrations of API manufacturing?

The global manufacturing of bulk APIs is geographically concentrated, with specific regions dominating production due to factors like cost, infrastructure, skilled labor, and regulatory history.

Major API Manufacturing Hubs:

• China: China is the world's largest producer of APIs. It has a vast network of manufacturing facilities, ranging from large state-owned enterprises to numerous private companies. China offers significant cost advantages and has invested heavily in upgrading its manufacturing capabilities and compliance with international GMP standards. Many global pharmaceutical companies source intermediates and APIs from China. Regulatory oversight by the NMPA (National Medical Products Administration) has been evolving.
• India: India is the second-largest producer of APIs globally and is often referred to as the "pharmacy of the world." Indian API manufacturers are well-established, with many holding FDA and EMA approvals and supplying APIs to regulated markets worldwide. The country has a strong base of skilled chemists and engineers, coupled with competitive manufacturing costs. Regulatory oversight by the CDSCO (Central Drugs Standard Control Organisation) is in place, with increasing emphasis on quality.
• Europe: European countries, particularly Germany, Switzerland, Italy, and Spain, have a significant presence in high-value and complex API manufacturing. These manufacturers often focus on specialized chemistries, high-potency APIs, and operate under the strictest GMP and environmental regulations. While costs are generally higher, the proximity to major pharmaceutical markets, robust regulatory frameworks, and strong IP protection are key advantages.
• United States: The U.S. has a notable API manufacturing sector, with many companies specializing in niche products, high-potency APIs, and advanced therapeutic areas. There has been a push to reshore some API manufacturing to enhance supply chain security, though cost remains a significant factor. FDA oversight is the primary regulatory driver.

Table 2: Geographic Distribution of API Manufacturing Capabilities

Region	Dominant Capabilities	Key Factors
China	High-volume production, Cost-effective synthesis, Broad range of chemicals, Intermediates, Generic APIs	Lower labor and operational costs, Large domestic market, Significant investment in infrastructure, Evolving regulatory framework (NMPA)
India	High-volume production, Cost-effective synthesis, Strong in generics, Growing expertise in complex APIs, Significant FDA/EMA approved facilities	Skilled workforce, Competitive pricing, Established export market, Robust regulatory framework (CDSCO)
Europe	High-value, complex APIs, Specialized chemistries, High-potency APIs, Innovative synthesis routes, Strict quality and environmental standards	Strong R&D capabilities, High regulatory standards (EMA), Proximity to markets, Established IP protection, Higher operational costs
North America	Niche APIs, High-potency APIs, Biologics APIs (though less relevant for small molecules like ivosidenib), Advanced therapeutic areas, Supply chain security focus	Stringent regulatory oversight (FDA), Growing emphasis on domestic production, High operational costs, Strong innovation ecosystem

The choice of manufacturing location for ivosidenib API will likely involve a balance of cost, regulatory compliance, technical capability, and supply chain risk assessment. Companies often seek to diversify their sourcing across different regions to mitigate risks.

What are the key considerations for API procurement for TIBSOVO?

Securing a reliable and high-quality supply of ivosidenib API involves several critical considerations for pharmaceutical companies. These factors extend beyond simple vendor selection and encompass strategic supply chain management.

1. Manufacturing Capacity and Scalability:

• Current Capacity: Assess the current production capacity of potential suppliers. Does it align with projected commercial demand for TIBSOVO, considering existing and planned indications?
• Scalability: Can the supplier rapidly scale up production to meet unforeseen demand surges or expansion into new markets? This requires robust manufacturing infrastructure and supply chain flexibility.

2. Quality and Regulatory Compliance:

• GMP Certification: Verify that all manufacturing sites are GMP-certified by major regulatory bodies (FDA, EMA, etc.) and that these certifications are current.
• Inspection History: Review the history of regulatory inspections (FDA Form 483 observations, warning letters) and internal audit findings for potential suppliers.
• Quality Management System (QMS): Evaluate the robustness of the supplier's QMS, including their procedures for change control, deviation management, CAPA (Corrective and Preventive Actions), and batch release.
• Impurity Control: Thoroughly understand the supplier's impurity profile for ivosidenib and their strategies for controlling critical impurities, especially genotoxic ones.

3. Technical Expertise and Process Understanding:

• Synthesis Route: Is the supplier's synthesis route for ivosidenib well-understood, efficient, and robust? Have they demonstrated expertise in handling the specific chemical transformations involved?
• Process Development Capabilities: For new suppliers or for lifecycle management, assess their ability to optimize the manufacturing process for yield, cost, and environmental impact.
• Analytical Capabilities: Ensure the supplier has sophisticated analytical capabilities for raw material testing, in-process controls, and final API release testing.

4. Supply Chain Security and Risk Management:

• Raw Material Sourcing: Understand the supplier's own raw material sourcing strategy. Are their key starting materials and intermediates sourced reliably and from qualified vendors?
• Geographic Diversification: Consider sourcing from manufacturers located in different geographic regions to mitigate risks associated with geopolitical events, natural disasters, or localized regulatory changes.
• Business Continuity Planning: Assess the supplier's business continuity and disaster recovery plans to ensure uninterrupted supply.
• Inventory Management: Evaluate their inventory management practices for raw materials, intermediates, and finished API.

5. Cost and Commercial Terms:

• Pricing: Obtain competitive quotes and understand the cost drivers for the API. Negotiate pricing based on volume commitments and long-term agreements.
• Payment Terms: Establish clear payment terms and currency considerations.
• Intellectual Property: Ensure that the chosen manufacturing process does not infringe on any existing patents and that the supplier has the right to produce and sell the API.

6. Supplier Relationship Management:

• Communication and Transparency: Foster open and transparent communication channels with the API supplier.
• Partnership Approach: Seek suppliers who are willing to operate as strategic partners, collaborating on process improvements and risk mitigation.
• Contractual Agreements: Establish comprehensive supply agreements that clearly define quality standards, delivery schedules, pricing, intellectual property rights, and termination clauses.

For TIBSOVO, a targeted therapy with a significant impact on patient outcomes, ensuring a consistent, high-quality API supply is non-negotiable. A proactive and thorough procurement strategy is essential.

Key Takeaways

• The bulk API for TIBSOVO (ivosidenib) is a complex small molecule requiring specialized manufacturing capabilities.
• Key sourcing challenges include manufacturing complexity, stringent regulatory requirements (GMP), intellectual property, and supply chain security.
• Potential API manufacturers are primarily global Contract Development and Manufacturing Organizations (CDMOs) and specialized API producers with expertise in oncology drugs.
• Major manufacturing hubs for APIs are China and India, offering cost advantages and large-scale capacity, while Europe and North America provide specialized capabilities and stringent regulatory oversight.
• Procurement strategies must prioritize regulatory compliance (GMP, DMFs), manufacturing capacity and scalability, robust quality management systems, supply chain security, and a collaborative supplier relationship.

Frequently Asked Questions

• Q1: How does the patent status of TIBSOVO affect API sourcing? The patent status of TIBSOVO's composition of matter and key use patents is crucial. While the primary patents may be expiring or have expired, patents covering specific manufacturing processes, polymorphs, or formulations can still influence the freedom to operate for API manufacturers and potentially restrict certain synthesis routes or API forms.

• Q2: What is the role of a Drug Master File (DMF) in API sourcing for TIBSOVO? A DMF is a submission to regulatory authorities (like the FDA) by the API manufacturer. It contains confidential, detailed information about the API's manufacturing, facility, and controls. The drug product manufacturer references this DMF in their drug application, allowing regulatory agencies to review the API's quality without the API manufacturer disclosing proprietary information directly to the drug product company.

• Q3: Can generic manufacturers of ivosidenib API pose a challenge to branded supply? As patents for TIBSOVO expire, generic manufacturers may enter the market. This competition can drive down API prices and potentially increase the number of API suppliers. However, for branded TIBSOVO, the initial supply chain is typically secured through established contracts with qualified CDMOs or in-house manufacturing capabilities before generic competition becomes a significant factor for the innovator drug.

• Q4: How are high-potency APIs (HPAPIs) handled in the context of ivosidenib manufacturing? Ivosidenib, being an oncology drug, may be classified as a high-potency API depending on its therapeutic dose and occupational exposure limits. HPAPI manufacturing requires specialized containment facilities, safety protocols, and trained personnel to protect workers and the environment from exposure. Manufacturers capable of handling HPAPIs are specifically sought for such APIs.

• Q5: What are the implications of supply chain disruptions on ivosidenib API procurement? Supply chain disruptions, such as those caused by geopolitical events, natural disasters, or pandemics, can severely impact the availability of critical APIs like ivosidenib. Pharmaceutical companies mitigate this risk by diversifying their supplier base across different geographic regions, establishing dual-sourcing strategies, and maintaining strategic inventory levels.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry

[2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4. Good Manufacturing Practice. Retrieved from https://ec.europa.eu/health/human-use/eudralex

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/search-guidelines

[4] National Medical Products Administration (China). (n.d.). Official website. (Information accessed via industry reports and official government portals).

[5] Central Drugs Standard Control Organisation (India). (n.d.). Official website. (Information accessed via industry reports and official government portals).